RMS Regrow has received accreditation with ISO 13485:2003 for their therapies, Chondron and Ossron; and cord blood banking service, BabyCell.
With this development, RMS Regrow has become India's first cell therapy company to provide quality services of international standards to its customers and associates.
ISO 13485:2003 specifies requirements for a quality management system where an organisation needs to demonstrate its ability to provide medical devices and related services that consistently meet customer requirements and regulatory requirements applicable to medical devices and related services. The primary objective of ISO 13485:2003 is to facilitate harmonised medical device regulatory requirements for quality management systems.
Informing about the ISO certification, Dr Vinayak V Kedage, lab director, RMS Regrow said, "The ISO 13485:2003 will ensure that our medical devices and related services will now be in compliance with global standards. This certification will further build trust and confidence of RMS amongst its customers and associates."
Through a strategic partnership with Sewon Cellontech, RMS offers the new cartilage implantation and bone regeneration solutions, Chondron and Ossron; and cord blood banking service BabyCell. RMS Regrow has recently signed multi-hospital agreements to provide this therapy to as many patients.
RMS Regrow is focused in the delivery of the most advanced cell therapy treatments. Regenerative medicine has been known as a promising alternative to human tissue or organ transplantation. After years of R&D, new treatments were developed to allow fast and effective cartilage and bone repair, with permanent results, giving new hope for patients to live in healthy and active life.